Medicus Pharma's SkinJect Shows Dose-Dependent Efficacy in Nodular BCC Trial
Event summary
- Medicus Pharma's expanded Phase 2 SKNJCT-003 analysis showed dose-dependent efficacy of D-MNA in treating nodular basal cell carcinoma (BCC), with 64% clinical clearance at Day 57 in the 200µg cohort.
- The study enrolled 90 participants, with 69 meeting the intended nodular BCC inclusion criteria after central pathology reconciliation.
- The 200µg D-MNA cohort demonstrated progressive improvement from Day 29 to Day 57, suggesting a drug-driven therapeutic effect.
- No drug-related serious adverse events were reported, with predominantly mild localized treatment-site reactions.
- The company plans to use these findings to advance toward End-of-Phase 2 (EOP2) discussions with the FDA.
The big picture
Medicus Pharma's positive dose-response data for SkinJect reinforces its potential to disrupt the BCC treatment landscape, offering a non-surgical alternative with rapid efficacy. The company's strategic collaborations, including with Helix Nanotechnologies and the Gorlin Syndrome Alliance, position it to expand its pipeline and address broader skin oncology needs. The upcoming EOP2 discussions with the FDA will be critical in determining the regulatory pathway for SkinJect's commercialization.
What we're watching
- Regulatory Pathway
- Whether the FDA will accept the expanded dataset as sufficient for a registrational path, given the clear dose-response relationship and favorable safety profile.
- Commercial Potential
- The pace at which Medicus can translate these results into a market-ready product, addressing a significant unmet need in BCC treatment.
- Competitive Positioning
- How SkinJect's rapid onset efficacy and non-surgical approach will differentiate it from existing therapies in the $2 billion BCC market.
Related topics